Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time
- 30 June 2008
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 179 (6), 2181-2186
- https://doi.org/10.1016/j.juro.2008.01.099
Abstract
Purpose: Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific an...This publication has 20 references indexed in Scilit:
- Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause MortalityJournal of Clinical Oncology, 2007
- Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancerUrology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen FailureJournal of Clinical Oncology, 2005
- A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPYJournal of Urology, 2005
- Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancerUrology, 2004
- Temporal (circadian) and functional relationship between prostate-specific antigen and testosterone in healthy menUrology, 1995
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor responseUrology, 1989